Our News section keeps you up to speed with the latest developments at Cytel.
Waltham, MA, October 6, 2020 – Cytel Inc. has launched SolaraTM, a collaborative decision-support platform that revolutionizes the identification of optimal clinical trial designs for greater business results for biotech and pharmaceutical companies.
Two South Africa sites added to TOGETHER platform trials for the outpatient treatment of high-risk adults infected with SARS-CoV-2
Cytel Inc. has significantly widened the geographical scope of the TOGETHER trial, a unique study to identify early COVID-19 interventions in underserved low- and middle-income country (LMIC) populations. The trial, supported with seed funding from the Bill & Melinda Gates Foundation, is one of the very few studies investigating therapies at the earliest stages of COVID-19 infection, and is the only trial to explore early interventions in the Global South. The expansion consists of two new sites in South Africa to complement the study sites actively recruiting in Brazil and the United States. By leveraging its expertise in such complex trial designs, Cytel’s Global Health team is making a lasting contribution to local trial infrastructure to support future clinical investigation in these vulnerable populations.
Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. The acquisition further builds Cytel’s dedicated team of Bayesian experts to include several new and highly esteemed biostatisticians led by renowned Bayesian design specialist Dr. Yuan Ji, who also jointly holds an appointment as Professor of Biostastistics at the University of Chicago. The deal follows the recent release of Cytel’s East Alloy platform for easy access to verified Bayesian tools, and marks the latest step in Cytel’s commitment to broadening industry access to the most innovative clinical trial design methods.
Cytel Inc., an advanced
Global COVID-19 Clinical Trial Tracker
Cytel Inc. has launched an open-access global COVID-19 Clinical Trial Tracker to help facilitate greater collaboration between researchers, policymakers, clinicians, journalists, philanthropists, and other critical stakeholders who need to understand the complex dynamics of the global response to finding a solution to the COVID-19 outbreak.
Collaboration to accelerate new clinical trial technologies and techniques for disease-focused RWE production
Clinical trial biostatistics and advanced data analytics leader Cytel Inc. joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS) initiative as a strategic partner.
Waltham MA, March 04, 2020 — A new paper authored by statistical experts at Cytel has been published in the world-renowned journal CA: A Cancer Journal for Clinicians. The open-access paper, titled ‘An Overview of Precision Oncology Basket and Umbrella Trials for Clinicians,’ provides a valuable resource for increasing master protocol trial literacy among the many clinicians and researchers who may not be familiar with these innovative trial types. Such trials offer considerable potential value in more rapidly bringing new oncology therapeutics to patients. However, there is a critical need for improved understanding in order to optimize their use. To further address this need, Jay Park, Director at Cytel and lead author on the article, will host a free 60-minute webinar on March 19, to expand on the contents of the article, discussing the unique features of umbrella and basket trials and outlining the key considerations for their successful design and implementation.
Copenhagen, Denmark —ISPOR Europe 2019 —November 05 2019—Cytel Inc. (“Cytel” or the “Company”), the leading provider of innovative analytical software and consulting services to the biopharmaceutical sector, and a portfolio company of New Mountain Capital, today announced that it has acquired MTEK Sciences (“MTEK”) to further expand its advanced real-world analytics (RWA) capabilities.
Cytel Inc., the leading global provider of innovative analytical software and consulting services to the life sciences industry, has announced that the Complex Innovative Trial Design Symposium and East® Training will take place November 6–7 at Alexion’s headquarters in Boston, Massachusetts. The event will bring together industry-leading experts to discuss innovative solutions to pressing challenges including rare disease clinical trials.
Cytel launches East On Demand bringing adaptive clinical trial design capabilities to wider biopharma audience
Cytel Inc., the leading global provider of analytical solutions to the life sciences industry, today announced that it will launch East On Demand™ at the annual Joint Statistical Meetings (JSM) 2019 (July 27 – August 1, Denver, Colorado). Offered via the cloud and licensed through subscriptions, East On Demand provides statisticians with more flexible access to East, the industry standard software package for the effective design of adaptive and innovative clinical trials.
Cytel and Axio join forces to create an industry leader in analytical solutions for drug development
Cytel Inc., the leading global provider of innovative analytical software and services to the life sciences industry, and Axio Research, a premier provider of biostatistics to pharmaceutical, biotechnology and medical device companies, today announced that they have joined forces to create the largest global biometrics organization focused on delivering advanced analytical solutions for the life sciences industry. The merged business will operate under the Cytel brand, with Axio continuing to provide its renowned data monitoring committee services for clinical trials, as “Axio, a Cytel company.”
Cytel announced the appointment of Joshua Schultz as Chief Executive Officer (CEO) effective January 7th, 2019. He succeeds Joseph Avellone, who acted as Cytel’s interim CEO from March 2018 and will continue to serve on the company’s Board of Directors.
Mr. Schultz is an accomplished leader with a 20-year track record of success in life sciences and clinical research organizations. He joins Cytel from PAREXEL, where he most recently served as an Officer of the company and Senior Vice President for its Access business unit.
Cytel announced the launch of OK GO, the first commercially available software to underpin quantitative go/no-go decision-making frameworks in clinical trials. The innovative product helps sponsors make faster, more robust decisions about their products to improve their R&D productivity. OK GO is the commercial release of custom software originally developed as a collaboration between AstraZeneca and Cytel scientists to enhance the established decision-making framework in AstraZeneca’s early clinical development group.
Cytel has won Best Contract Research Organization( CRO) – Specialist Providers at the 2018 Scrip Awards. The accolade was presented to Cytel at an awards ceremony in London on 28th November 2018. The Scrip Awards acknowledge the pharmaceutical and biotechnology industry’s highest achievers across the value chain. The Best Contract Research Organization – Specialist Providers category highlights the critical role that CROs play in drug development, and particularly commends quality of service and strength of customer relationships. Cytel was selected as the winner by an independent panel of senior industry experts.
Cytel Inc., a global provider of advanced analytical solutions to the pharmaceutical, biotechnology, and medical device industries, today announced the launch of East® version 6.5, further enhancing the most trusted technology platform for designing, monitoring, and simulating adaptive trials. Since 1995, East has empowered trial sponsors of all sizes to optimize study planning and monitoring efforts, accelerate
The free tool is available for download on the App Store and gives biostatisticians the ability to conveniently and quickly create sample size and power calculations using their iPhone or iPad.
Congratulations to Lipopharma and the CLINGLIO project consortium on their recent 6,15M€ grant award by the European Union’s Horizon 2020 program. Led by Lipopharma, the multinational consortium brings together 12 academic and industry organizations from Europe, Israel, and the USA.
Cytel collaborated with Lipopharma and the consortium to create the innovative trial design and provided statistical input for the successful grant application.